Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.

Ikari J, Michalski JM, Iwasawa S, Gunji Y, Nogel S, Park JH, Nelson AJ, Farid M, Wang X, Schulte N, Basma H, Toews ML, Feghali-Bostwick C, Tenor H, Liu X, Rennard SI.

Am J Respir Cell Mol Biol. 2013 Oct;49(4):571-81. doi: 10.1165/rcmb.2013-0004OC.

PMID:
23656623
2.

Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4.

Michalski J, Kanaji N, Liu X, Nogel S, Wang X, Basma H, Nakanishi M, Sato T, Gunji Y, Fahrid M, Nelson A, Muller KC, Holz O, Magnussen H, Rabe KF, Toews ML, Rennard SI.

Am J Respir Cell Mol Biol. 2012 Dec;47(6):729-37. doi: 10.1165/rcmb.2012-0057OC. Epub 2012 Oct 4.

PMID:
23043089
3.

PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.

Togo S, Liu X, Wang X, Sugiura H, Kamio K, Kawasaki S, Kobayashi T, Ertl RF, Ahn Y, Holz O, Magnussen H, Fredriksson K, Skold CM, Rennard SI.

Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69. doi: 10.1152/ajplung.00508.2007. Epub 2009 Mar 20.

4.

Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts.

Nakanishi M, Sato T, Li Y, Nelson AJ, Farid M, Michalski J, Kanaji N, Wang X, Basma H, Patil A, Goraya J, Liu X, Togo S, L Toews M, Holz O, Muller KC, Magnussen H, Rennard SI.

Am J Respir Cell Mol Biol. 2012 Feb;46(2):217-23. doi: 10.1165/rcmb.2010-0115OC.

5.
6.

PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.

Kwak HJ, Park KM, Choi HE, Chung KS, Lim HJ, Park HY.

Cell Signal. 2008 May;20(5):803-14. doi: 10.1016/j.cellsig.2007.12.011. Epub 2007 Dec 28.

PMID:
18276108
8.
9.

Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells.

Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM.

Invest Ophthalmol Vis Sci. 1998 Mar;39(3):581-91.

PMID:
9501870
10.

Phosphodiesterase inhibitors in airways disease.

Fan Chung K.

Eur J Pharmacol. 2006 Mar 8;533(1-3):110-7. Epub 2006 Feb 2. Review.

PMID:
16458289
11.

A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.

Sabatini F, Petecchia L, Boero S, Silvestri M, Klar J, Tenor H, Beume R, Hatzelmann A, Rossi GA.

Pulm Pharmacol Ther. 2010 Aug;23(4):283-91. doi: 10.1016/j.pupt.2010.02.004. Epub 2010 Mar 11.

PMID:
20226872
12.

Roflumilast partially reverses smoke-induced mucociliary dysfunction.

Schmid A, Baumlin N, Ivonnet P, Dennis JS, Campos M, Krick S, Salathe M.

Respir Res. 2015 Oct 31;16:135. doi: 10.1186/s12931-015-0294-3.

13.

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H.

Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7. Review.

PMID:
20381629
14.

Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.

Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J.

Respir Res. 2006 Jan 19;7:9.

15.

Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition.

Selige J, Tenor H, Hatzelmann A, Dunkern T.

J Cell Physiol. 2010 May;223(2):317-26. doi: 10.1002/jcp.22037.

PMID:
20082309
16.

The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts.

Dagouassat M, Gagliolo JM, Chrusciel S, Bourin MC, Duprez C, Caramelle P, Boyer L, Hue S, Stern JB, Validire P, Longrois D, Norel X, Dubois-Randé JL, Le Gouvello S, Adnot S, Boczkowski J.

Am J Respir Crit Care Med. 2013 Apr 1;187(7):703-14. doi: 10.1164/rccm.201208-1361OC.

PMID:
23328527
17.

Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.

Milara J, Peiró T, Serrano A, Guijarro R, Zaragozá C, Tenor H, Cortijo J.

Pulm Pharmacol Ther. 2014 Aug;28(2):138-48. doi: 10.1016/j.pupt.2014.02.001. Epub 2014 Feb 11.

PMID:
24525294
18.

PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.

Lehrke M, Kahles F, Makowska A, Tilstam PV, Diebold S, Marx J, Stöhr R, Hess K, Endorf EB, Bruemmer D, Marx N, Findeisen HM.

J Mol Cell Cardiol. 2015 Apr;81:23-33. doi: 10.1016/j.yjmcc.2015.01.015. Epub 2015 Jan 30.

PMID:
25640159
19.

Effect of prostaglandin e2 on vascular endothelial growth factor production in nasal polyp fibroblasts.

Han DY, Cho JS, Moon YM, Lee HR, Lee HM, Lee BD, Baek BJ.

Allergy Asthma Immunol Res. 2013 Jul;5(4):224-31. doi: 10.4168/aair.2013.5.4.224. Epub 2013 May 27.

Items per page

Supplemental Content

Write to the Help Desk